Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Developmental exposure to an environmentally relevant dose of Bisphenol S impairs postnatal growth and disrupts placental transcriptional profile in female rat.

Reproductive toxicology (Elmsford, N.Y.)·2025

Same author

[Timing of gonadectomy in patients with complete androgen insensitivity syndrome].

Revue medicale de Liege·2022

Same author

[The treatments of hyperthyroidism].

Revue medicale de Liege·2022

Same author

[Nasal glucagon (Baqsimi®), new treatment for hypoglycaemic coma].

Revue medicale de Liege·2022

Same author

[Thyroiditis].

Revue medicale de Liege·2022

Same author

[Prospective study of the worry's effects on the psychological adjustment among parents of a child with type 1 diabetes.]

Revue medicale de Liege·2021

Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026

Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026

Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026

Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026

Same journal

[Climate change and skin].

Revue medicale de Liege·2026

Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 5, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

[Neonatal hyperthyroidism: clinical pattern and therapy].

S Petignot¹, K Nyamugabo, H Valdes Socin

¹Université de Liège, Belgique.

Revue Medicale De Liege

|December 5, 2013

Summary

This summary is machine-generated.

Neonatal hyperthyroidism, often caused by maternal Graves' disease, affects 1-2% of infants born to affected mothers. This study reviews four cases and discusses updated management strategies from fetal development through birth.

More Related Videos

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Published on: October 6, 2023

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

Related Experiment Videos

Last Updated: May 5, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Published on: October 6, 2023

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

Area of Science:

Endocrinology
Neonatology
Obstetrics

Background:

Neonatal hyperthyroidism is a rare condition, frequently linked to maternal Graves' disease.
Graves' disease affects approximately 0.2% of pregnant women.
Infants born to mothers with Graves' disease have a 1-2% risk of developing neonatal hyperthyroidism.

Observation:

This article presents a retrospective review of four neonatal hyperthyroidism cases diagnosed and treated at CHU-NDB between 2007 and 2011.
The cases highlight the clinical presentation and management of affected neonates.

Findings:

The study details the diagnostic and therapeutic approaches used for these four infants.
It provides insights into the practical management of neonatal hyperthyroidism in a clinical setting.

Implications:

Updated recommendations for managing neonatal hyperthyroidism from the fetal stage to birth are discussed.
This review aims to inform clinical practice and improve outcomes for affected neonates and their mothers.
The findings contribute to the evolving understanding of neonatal hyperthyroidism management protocols.